FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207785> ?p ?o ?g. }

• W4387207785 endingPage "S153" @default.
• W4387207785 startingPage "S153" @default.
• W4387207785 abstract "ART is a standard treatment used to reduce the risk of metastasis and recurrence in moderate‒to‒high-risk cSCC patients. Indications for ART have been largely based on pathologic risk factors and informed by staging systems, and while radiation oncologists generally designate a >10% risk threshold for usage of ART, there is no consensus on which groups of tumors may benefit from ART. The 40-GEP test has been independently validated to predict a cSCC patient's risk for regional/distant metastasis in patients with one or more high-risk clinicopathologic factors and reports three biologic risk groups: Class 1 (low, ∼7%), Class 2A (moderate, 20-25%), and Class 2B (high risk, >50%) for metastasis. This study aims to evaluate whether a biomarker informed risk stratification approach using a 40-GEP result could refine the ability to select patients with node negative cSCC at higher risk of metastasis who are most likely to benefit from ART.In this retrospective study, all patients had primary cSCC tissue with verified clinicopathologic information of tumors with one or more high-risk factors, met clinical testing criteria, were comprehensively staged, and had outcomes data (n = 954). Patients with node positive disease, or those with nodal failure within 3 months of diagnosis were excluded (n = 19). From the n = 935, an intermediate risk population wherein ART is often considered was defined as Brigham and Women's Hospital (BWH) ≥T2a (n = 489). Kaplan-Meier survival analysis and log-rank test were used to assess metastasis free survival (MFS). Univariate Cox regression compared metastasis rates between 40-GEP results.The 3-year MFS rate for this eligible for ART cohort was 82.4% The 40-GEP demonstrated statistically significant risk stratification with MFS rates of 92.4%, 76.1% and 59.4% for Class 1, Class 2A and Class 2B, respectively (p<0.0001). Cox regression was significant for Class 2A and 2B compared to Class 1, with a 3.2-fold and 6.4-fold increase in metastasis, respectively (p<0.0001). 64% (59/92) of all metastases received a Class 2A result, and 44% (14/32) of Class 2B patients metastasized. 46% (223/489) of the cohort received a Class 1 result. Of patients staged BWH T1 (n = 446), those with a Class 2A and 2B had an 88.7% and 66.7% MFS rate, respectively.Within this eligible for ART population, patients with Class 2A or 2B 40-GEP results have inferior rates of MFS, while Class 1 patients have <10% risk of metastasis. Nearly half of this population received a 40-GEP Class 1 result and could be considered for treatment de-intensification trials. Conversely, patients with low-risk BWH T1 stage, who are traditionally not considered for ART, that received a Class 2A or 2B (>10% risk of metastasis) could be considered for adjuvant therapy." @default.
• W4387207785 created "2023-09-30" @default.
• W4387207785 creator A5011221111 @default.
• W4387207785 creator A5029397040 @default.
• W4387207785 creator A5031633287 @default.
• W4387207785 creator A5043968037 @default.
• W4387207785 creator A5045735147 @default.
• W4387207785 creator A5065481778 @default.
• W4387207785 creator A5075197376 @default.
• W4387207785 creator A5078011374 @default.
• W4387207785 date "2023-10-01" @default.
• W4387207785 modified "2023-10-17" @default.
• W4387207785 title "Risk-Stratification using the 40-Gene Expression Profile (40-GEP) Test Identifies Patients with Node Negative Cutaneous Squamous Cell Carcinoma (cSCC) at Higher Risk of Metastasis Who May Benefit from Adjuvant Radiation Therapy (ART)" @default.
• W4387207785 doi "https://doi.org/10.1016/j.ijrobp.2023.06.575" @default.
• W4387207785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784387" @default.
• W4387207785 hasPublicationYear "2023" @default.
• W4387207785 type Work @default.
• W4387207785 citedByCount "0" @default.
• W4387207785 crossrefType "journal-article" @default.
• W4387207785 hasAuthorship W4387207785A5011221111 @default.
• W4387207785 hasAuthorship W4387207785A5029397040 @default.
• W4387207785 hasAuthorship W4387207785A5031633287 @default.
• W4387207785 hasAuthorship W4387207785A5043968037 @default.
• W4387207785 hasAuthorship W4387207785A5045735147 @default.
• W4387207785 hasAuthorship W4387207785A5065481778 @default.
• W4387207785 hasAuthorship W4387207785A5075197376 @default.
• W4387207785 hasAuthorship W4387207785A5078011374 @default.
• W4387207785 hasConcept C121608353 @default.
• W4387207785 hasConcept C126322002 @default.
• W4387207785 hasConcept C137345334 @default.
• W4387207785 hasConcept C143998085 @default.
• W4387207785 hasConcept C144301174 @default.
• W4387207785 hasConcept C167135981 @default.
• W4387207785 hasConcept C2779013556 @default.
• W4387207785 hasConcept C2908647359 @default.
• W4387207785 hasConcept C38180746 @default.
• W4387207785 hasConcept C50382708 @default.
• W4387207785 hasConcept C66339696 @default.
• W4387207785 hasConcept C71924100 @default.
• W4387207785 hasConcept C99454951 @default.
• W4387207785 hasConceptScore W4387207785C121608353 @default.
• W4387207785 hasConceptScore W4387207785C126322002 @default.
• W4387207785 hasConceptScore W4387207785C137345334 @default.
• W4387207785 hasConceptScore W4387207785C143998085 @default.
• W4387207785 hasConceptScore W4387207785C144301174 @default.
• W4387207785 hasConceptScore W4387207785C167135981 @default.
• W4387207785 hasConceptScore W4387207785C2779013556 @default.
• W4387207785 hasConceptScore W4387207785C2908647359 @default.
• W4387207785 hasConceptScore W4387207785C38180746 @default.
• W4387207785 hasConceptScore W4387207785C50382708 @default.
• W4387207785 hasConceptScore W4387207785C66339696 @default.
• W4387207785 hasConceptScore W4387207785C71924100 @default.
• W4387207785 hasConceptScore W4387207785C99454951 @default.
• W4387207785 hasIssue "2" @default.
• W4387207785 hasLocation W43872077851 @default.
• W4387207785 hasLocation W43872077852 @default.
• W4387207785 hasOpenAccess W4387207785 @default.
• W4387207785 hasPrimaryLocation W43872077851 @default.
• W4387207785 hasRelatedWork W2050604659 @default.
• W4387207785 hasRelatedWork W2160911489 @default.
• W4387207785 hasRelatedWork W2361700749 @default.
• W4387207785 hasRelatedWork W2386134303 @default.
• W4387207785 hasRelatedWork W2395438194 @default.
• W4387207785 hasRelatedWork W2539752444 @default.
• W4387207785 hasRelatedWork W4200103625 @default.
• W4387207785 hasRelatedWork W4200194158 @default.
• W4387207785 hasRelatedWork W4226367882 @default.
• W4387207785 hasRelatedWork W4381839216 @default.
• W4387207785 hasVolume "117" @default.
• W4387207785 isParatext "false" @default.
• W4387207785 isRetracted "false" @default.
• W4387207785 workType "article" @default.